Gilead and Kite Present Pipeline Data at ASH 2026
The companies reported iMMagine-1 data with at least 18 months of follow-up on anito-cel durability and safety in relapsed disease.
The companies reported iMMagine-1 data with at least 18 months of follow-up on anito-cel durability and safety in relapsed disease.